Immediate Breast Reconstruction With Free Greater Omentum
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03370250 |
|
Recruitment Status :
Recruiting
First Posted : December 12, 2017
Last Update Posted : December 12, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease |
|---|
| Breast Reconstruction |
| Study Type : | Observational |
| Estimated Enrollment : | 20 participants |
| Observational Model: | Case-Only |
| Time Perspective: | Retrospective |
| Official Title: | Immediate Breast Reconstruction With Free Greater Omentum for Luminal Breast Cancer Patients |
| Actual Study Start Date : | November 1, 2017 |
| Actual Primary Completion Date : | December 3, 2017 |
| Estimated Study Completion Date : | December 31, 2023 |
- severe related complication [ Time Frame: 1 year after surgery ]Serious adverse effect occur within 1 years after implantation
- cosmetic outcome [ Time Frame: 6 months after surgery ]Four-point scale was formulated to evaluate the cosmetic score as excellent (size and shape of recon-structed breast are identical to the original breast); good (deformity of the reconstructed breast in-volved less than 1/4 of the original breast; fair (deformity of the reconstructed breast involves less than 1/4-1/2 of the original breast); and poor (breast deformity involves more than 1/2 of the original breast)
- greater omentum survival [ Time Frame: 2 and 5 years after surgery ]At each follow up time point the proportion of patients with omentum transplantation will be estimated.
- Patient satisfaction [ Time Frame: 6months, 1 and 2 years after surgery ]Patients also rate their level of satisfaction, with the help of a numeric rating scale (NRS: 0-10), in terms of how the outcome met up to their preoperative expectations of the arthroplasty. Finally, they will be asked whether - with their current knowledge of the outcome - they would again choose the operation if they found themselves in similar circumstances to those which prevailed preoperatively.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Inclusion Criteria:
- Patient aged 18 -60 years Patient diagnosed with luminal breast cancer No neoadjuvant chemotherapy previously No distant metastasis Suitable for breast conserving surgery Willing and able to give written informed consent to participate in the study including all follow-up examinations
Exclusion Criteria:
- Participate in another clinicaltrial Bilateral lesions Pregnancy or lactation Greater omentum unable to extract or insufficient omentum Other surgical contraindication
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03370250
| Contact: Mei ling Huang, MD | 029-84775271 | huangmeiling@126.com |
| China, Shaanxi | |
| Xijing hospital | Recruiting |
| Xi'an, Shaanxi, China, 710032 | |
| Contact: Mei Ling Huang, MD 029-84775271 huangmeiling@126.com | |
| Responsible Party: | Xijing Hospital |
| ClinicalTrials.gov Identifier: | NCT03370250 |
| Other Study ID Numbers: |
KY20162047-1 |
| First Posted: | December 12, 2017 Key Record Dates |
| Last Update Posted: | December 12, 2017 |
| Last Verified: | December 2017 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
immediate breast reconstruction free greater omentum breast-conserving surgery luminal breast cancer |

